– XGEN Venture Announces Final Closing of the XGEN Venture Life Sciences Fund, raising approximately €180 million in total commitments.
– Surpassed expectations, solidifying its role as a key player in the European life sciences investment landscape.
– Targets early-stage investments in biotechnology, medical devices, and diagnostics.
– Strategic approach leverages a network of scientific experts, seasoned entrepreneurs, and industry leaders.
– Aims to accelerate growth and innovation, delivering transformative healthcare solutions to market.
– Deployed capital in six startups, including iOnctura B.V., which develops therapies for neglected and hard-to-treat cancers.
– Plans for nine additional investments over the next two to three years to complete the portfolio.
– Paolo Fundarò, Co-Founder & Managing Partner: Highlighted the critical role of innovation in addressing healthcare challenges. Expressed excitement about strong support from both existing and new investors.
– Federica Draghi, Co-Founder & Managing Partner: Emphasized the dual opportunity for societal impact and financial returns in life sciences. Leads the fund’s environmental, social, and governance (ESG) strategy.
– Daniele Scarinci, Co-Founder & Managing Partner: Shared ambitions to establish XGEN Venture as a leading European venture capital firm. Cited the success of the first fund and the team as a solid foundation for future growth.
– Extended gratitude to investors, including institutional investors, family offices, and high-net-worth individuals, for their confidence in XGEN Venture’s vision and expertise.
